Following are results of data recently released at the American Society of Clinical Oncology annual meeting in Chicago.

• AEterna Zentaris Inc., of Quebec City, said Phase I data showed evidence of antitumor activity with 160 mg/m2 or 267 mg/m2 doses of its targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analogue, AEZS-108, in female patients with cancers expressing LHRH receptors. Specifically, seven of 13 showed signs of tumor response, including three with complete or partial responses. Separately, the company's partner Keryx Biopharmaceuticals Inc., of New York, presented Phase I and II results showing that perifosine generated an overall clinical benefit rate of 52 percent, which compares favorably with the activity of mTOR inhibitors, in treating advanced sarcoma.

• Antisoma plc, of London, presented new data from its Phase II trials of ASA404 (formerly AS1404), a small-molecule vascular disrupting agent, with first-line docetaxel chemotherapy in hormone-refractory prostate cancer. Final PSA data showed a response rate of 59 percent for ASA404 plus docetaxel vs. 37 percent for docetaxel alone. The proportion of patients showing progression by PSA was 16 percent in the ASA404 group and 37 percent in the control group.

• ChemGenex Pharmaceuticals Ltd., of Melbourne, Australia, presented data from a Phase I/IIa trial of Quinamed (amonafide dihydrochloride) in heavily pretreated patients with solid tumors. It said it demonstrated that dose level could be optimized according to patient genotype, that the drug was well tolerated, and that anticancer activity was seen.

• Diatos SA, of Paris, presented Phase I data of the doxorubicin prodrug DTS-201, demonstrating safety, tolerability and the ability to deliver high doses of free doxorubicin in humans. It determined a recommended dose for Phase II trials of the drug, also known as Super-Leu-Dox or CPI-0004Na.

• GlaxoSmithKline plc, of London, reported positive data from three studies of its oral small-molecule HER2 kinase inhibitor, Tykerb. Data were presented on one study with paclitaxel as first-line treatment for advanced breast cancer; another showed Tykerb has clinical activity in heavily pretreated patients with CNS metastases from HER2-positive breast cancer; and a third found that fewer patients on Tykerb plus capecitabine developed brain metastases vs. capecitabine alone.

• Oxford BioMedica plc, of Oxford, UK, and Sanofi-aventis Group, of Paris, said Phase II data on 48 evaluable patients with progressive metastatic renal cell cancer showed the immunotherapy product TroVax was well tolerated and that it induced anti-5T4 antibody responses in 91 percent of patients. In patients with clear-cell RCC, disease control was shown in 24 of 35 evaluable patients. Preliminary analysis showed a statistically significant relationship between reduction in tumor burden and anti-5T4 antibody responses.

• Sigma-Tau SpA, of Pomezia, Italy, said thymalfasin (Zadaxin, thymosin alpha 1) achieved its primary endpoint in a Phase II trial treating patients diagnosed with Stage IV malignant melanoma. Results showed that thymalfasin in combination with dacarbazine (DTIC) chemotherapy tripled the overall response rate and extended overall survival by nearly three months compared to patients treated with DTIC, the current standard of care, and interferon alpha.

No Comments